Clinical Trials Browser

Has results × Cholangiocarcinoma × niraparib × Clear all

NCT03207347 2023-09-15

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Phase 2 Completed

37 enrolled 15 charts

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma